NanoViricides, Inc. has entered into a securities purchase agreement with a single healthcare institutional investor for a registered direct offering expected to generate approximately $6 million in gross proceeds. The company will sell 3,571,429 shares of common stock at $1.68 per share, with closing anticipated around November 12, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction.
In a concurrent private placement, NanoViricides will issue Series A and Series B warrants, each allowing purchase of up to 3,571,429 additional shares. The Series A warrants carry an exercise price of $1.75 per share and will be exercisable six months after issuance with a two-year expiration. The Series B warrants feature a $2.00 exercise price, becoming exercisable after six months and expiring in 5.5 years. Proceeds from the financing will be allocated to working capital and general corporate purposes.
This capital infusion is significant for advancing the company's clinical-stage antiviral development programs. NanoViricides is developing broad-spectrum antiviral nanomedicines using its proprietary nanoviricide technology platform licensed from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, represents a promising approach to treating multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, as well as MPOX/Smallpox infections.
The company's development pipeline extends beyond respiratory viruses to include NV-HHV-1 for Shingles treatment and programs targeting oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. Through its licensing agreement with TheraCour, NanoViricides holds exclusive worldwide perpetual licenses for specific targeting mechanisms against numerous viral pathogens. The company maintains its corporate information at https://www.nanoviricides.com.
This financing comes at a critical juncture as NanoViricides focuses on advancing NV-387 into Phase II human clinical trials. The development of broad-spectrum antiviral treatments addresses a significant unmet medical need, particularly given the ongoing challenges of emerging viral threats and pandemic preparedness. The company's platform technology, based on the TheraCour nanomedicine approach, offers potential advantages in targeting multiple viruses through specialized nanomaterials.
While the company acknowledges the inherent risks in pharmaceutical development, including the lengthy timeline and substantial capital requirements typical of drug development, this $6 million financing provides essential resources to continue progressing its antiviral portfolio. The successful development of these treatments could have substantial implications for global public health by providing new therapeutic options against multiple viral threats that currently lack effective treatments.
